Pharma Mar S.A./€PHM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Pharma Mar S.A.
Pharma Mar S.A. is a biopharmaceutical company based in Madrid, Spain, specializing in the research, development, and commercialization of marine-derived drugs. The company's core focus is on oncology, where it develops and produces antitumor drugs. Its product portfolio includes compounds such as Yondelis, Aplidin, and Zepzelca, each targeting various forms of cancer. Founded in 1986, Pharma Mar is part of the pharmaceutical group Zeltia. The company leverages its unique access to marine biodiversity to create differentiated products, positioning itself distinctively within the pharmaceutical industry. Pharma Mar operates globally, with a significant foothold in both European and international markets.
Ticker
€PHM
Sector
Primary listing
BME
Industry
Biotechnology
Headquarters
Employees
500
Website
Pharma Mar S.A. Metrics
BasicAdvanced
€1.5B
-
-
-0.11
€0.80
0.96%
Price and volume
Market cap
€1.5B
Beta
-0.11
52-week high
€104.76
52-week low
€34.72
Average daily volume
65K
Dividend rate
€0.80
Financial strength
Current ratio
2.969
Quick ratio
2.234
Long term debt to equity
20.376
Total debt to equity
26.302
Dividend payout ratio (TTM)
57.46%
Interest coverage (TTM)
2.34%
Profitability
EBITDA (TTM)
11.726
Gross margin (TTM)
94.41%
Net profit margin (TTM)
11.31%
Operating margin (TTM)
4.37%
Effective tax rate (TTM)
-83.17%
Revenue per employee (TTM)
€350,000
Management effectiveness
Return on assets (TTM)
1.44%
Return on equity (TTM)
10.19%
Valuation
Dividend yield (TTM)
0.96%
Growth
Revenue change (TTM)
8.39%
3-year revenue growth (CAGR)
-8.81%
3-year dividend per share growth (CAGR)
7.17%
Bulls say / Bears say
Pharma Mar's strategic share buyback program, including the repurchase of 7,563 shares in February 2025, demonstrates confidence in the company's value and aims to enhance shareholder returns. (TipRanks)
The company reported a significant increase in net income, reaching €18.68 million in Q4 2024, marking a 374% year-over-year growth, indicating strong financial performance. (Google Finance)
Pharma Mar's licensing agreement with Merck for the development and commercialization of Lurbinectedin in Japan expands its market presence and potential revenue streams. (MarketScreener)
Despite recent share price increases, Pharma Mar's revenue declined by 9.3% in the past year, raising concerns about its growth prospects. (Simply Wall St)
The company's P/S ratio of 9.9x is considered moderate, suggesting that investors may have tempered expectations regarding future revenue growth. (Simply Wall St)
A significant increase in short interest, with 32,700 shares shorted as of February 28, 2025, indicates that some investors are betting against the stock's performance. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 4 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharma Mar S.A. stock?
Pharma Mar S.A. (PHM) has a market cap of €1.5B as of July 28, 2025.
What is the P/E ratio for Pharma Mar S.A. stock?
The price to earnings (P/E) ratio for Pharma Mar S.A. (PHM) stock is 0 as of July 28, 2025.
Does Pharma Mar S.A. stock pay dividends?
Yes, the Pharma Mar S.A. (PHM) stock pays dividends to shareholders. As of July 28, 2025, the dividend rate is €0.8 and the yield is 0.96%. Pharma Mar S.A. has a payout ratio of 57.46% on a trailing twelve-month basis.
When is the next Pharma Mar S.A. dividend payment date?
The next Pharma Mar S.A. (PHM) dividend payment date is unconfirmed.
What is the beta indicator for Pharma Mar S.A.?
Pharma Mar S.A. (PHM) has a beta rating of -0.11. This means that it has an inverse relation to market volatility.